Lysophosphatidic acid downregulates tissue inhibitor of metalloproteinases, which are negatively involved in lysophosphatidic acid-induced cell invasion

Ovarian cancer is a highly metastatic disease. Lysophosphatidic acid (LPA) levels are elevated in ascites from ovarian cancer patients, but its potential role in ovarian cancer metastasis has just begun to be revealed. In this work, we show that LPA stimulates invasion of primary ovarian cancer cells, but not ovarian epithelial or borderline ovarian tumor cells, although these benign cells indeed respond to LPA in cell migration. We have found that LPA downregulates tissue inhibitor of metalloproteinases (TIMPs). TIMP2 and TIMP3 play functional role in LPA-induced invasion as negative regulators. Gi protein, phosphatidylinositol-3 kinase (PI3K), p38 mitogen-activated protein kinase (MAPK), cytosolic phospholipase A2 and urokinase type plasminogen activator (uPA) are required for LPA-induced cells invasion. TIMP3 may affect two independent downstream targets, vascular endothelial growth factor receptor and p38 MAPK. In vivo, LPA stimulates tumor metastasis in an orthotopic ovarian tumor model, which can be inhibited by a PI3K inhibitor, LY294002. In summary, LPA is likely a key component for promoting ovarian metastasis in vivo. LPA downregulates TIMP3, which may have targets other than metalloproteinases. Our in vivo metastasis mouse model is useful for studying the efficacy of therapeutic regimes of ovarian cancer.

[1]  G. Mills,et al.  Mechanisms for Lysophosphatidic Acid-induced Cytokine Production in Ovarian Cancer Cells* , 2004, Journal of Biological Chemistry.

[2]  G. Mills,et al.  Constitutive and lysophosphatidic acid (LPA)-induced LPA production: role of phospholipase D and phospholipase A2. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  N. Sugimoto,et al.  Rho-dependent, Rho kinase-independent inhibitory regulation of Rac and cell migration by LPA1 receptor in Gi-inactivated CHO cells. , 2006, Experimental cell research.

[4]  Yan Xu,et al.  Electrospray ionization mass spectrometry analysis of lysophospholipids in human ascitic fluids: comparison of the lysophospholipid contents in malignant vs nonmalignant ascitic fluids. , 2001, Analytical biochemistry.

[5]  Yiling Lu,et al.  Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery , 2005, Nature Reviews Drug Discovery.

[6]  U. Puistola,et al.  Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor. , 2005, Gynecologic oncology.

[7]  Zeneng Wang,et al.  Biology of LPA in health and disease. , 2004, Seminars in cell & developmental biology.

[8]  G. Mills,et al.  Critical role of lysophospholipids in the pathophysiology, diagnosis, and management of ovarian cancer. , 2002, Cancer treatment and research.

[9]  D. Fishman,et al.  Lysophosphatidic acid promotes matrix metalloproteinase (MMP) activation and MMP-dependent invasion in ovarian cancer cells. , 2001, Cancer research.

[10]  Ralph S Freedman,et al.  Ovarian cancer, the coagulation pathway, and inflammation , 2005, Journal of Translational Medicine.

[11]  G. Mills,et al.  Lysophospholipids activate ovarian and breast cancer cells. , 1995, The Biochemical journal.

[12]  M. Stack,et al.  Differential Regulation of Membrane Type 1-Matrix Metalloproteinase Activity by ERK 1/2- and p38 MAPK-modulated Tissue Inhibitor of Metalloproteinases 2 Expression Controls Transforming Growth Factor-β1-induced Pericellular Collagenolysis* , 2004, Journal of Biological Chemistry.

[13]  G. Mills,et al.  Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. , 2001, Journal of the National Cancer Institute.

[14]  S. Mok,et al.  Hypoxia enhances lysophosphatidic acid responsiveness in ovarian cancer cells and lysophosphatidic acid induces ovarian tumor metastasis in vivo. , 2006, Cancer research.

[15]  A. Krüger,et al.  Inhibition of Intraperitoneal Tumor Growth of Human Ovarian Cancer Cells by Bi- and Trifunctional Inhibitors of Tumor-Associated Proteolytic Systems , 2003, Biological chemistry.

[16]  Yan Xu,et al.  A novel laminin‐induced lysophosphatidic acid autocrine loop in the migration of ovarian cancer cells , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[17]  Y Chen,et al.  Evaluation of Plasma Lysophospholipids for Diagnostic Significance Using Electrospray Ionization Mass Spectrometry (ESI‐MS) Analyses , 2000, Annals of the New York Academy of Sciences.

[18]  A. Skubitz,et al.  Establishment of an in vitro assay to measure the invasion of ovarian carcinoma cells through mesothelial cell monolayers , 2004, Clinical & Experimental Metastasis.

[19]  G. Mills,et al.  Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. , 2002, Cancer research.

[20]  Li Feng,et al.  Lysophosphatidic acid is constitutively produced by human peritoneal mesothelial cells and enhances adhesion, migration, and invasion of ovarian cancer cells. , 2006, Cancer research.

[21]  K. Shigemasa,et al.  Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary. , 2000, International journal of oncology.

[22]  Yun-Ju Lai,et al.  TRIP6 Enhances Lysophosphatidic Acid-induced Cell Migration by Interacting with the Lysophosphatidic Acid 2 Receptor* , 2004, Journal of Biological Chemistry.

[23]  G. Mills,et al.  Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  G. Mills,et al.  Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  R. Labianca,et al.  Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma. , 2003, European journal of cancer.

[26]  L. Baudhuin,et al.  Akt activation induced by lysophosphatidic acid and sphingosine-1-phosphate requires both mitogen-activated protein kinase kinase and p38 mitogen-activated protein kinase and is cell-line specific. , 2002, Molecular pharmacology.

[27]  V. Magdolen,et al.  Novel Bi- and Trifunctional Inhibitors of Tumor-Associated Proteolytic Systems , 2003, Biological chemistry.

[28]  G. Mills,et al.  Enantioselective responses to a phosphorothioate analogue of lysophosphatidic acid with LPA3 receptor-selective agonist activity. , 2003, Journal of medicinal chemistry.

[29]  P. Wingfield,et al.  TIMP-2 Mediated Inhibition of Angiogenesis An MMP-Independent Mechanism , 2003, Cell.

[30]  Shuang Huang,et al.  Signaling Mechanisms Responsible for Lysophosphatidic Acid-induced Urokinase Plasminogen Activator Expression in Ovarian Cancer Cells* , 2005, Journal of Biological Chemistry.

[31]  Gordon B Mills,et al.  Lysophosphatidic acid is a bioactive mediator in ovarian cancer. , 2002, Biochimica et biophysica acta.

[32]  P. Steeg,et al.  Nm23/Nucleoside Diphosphate Kinase in Human Cancers , 2000, Journal of bioenergetics and biomembranes.

[33]  G. Mills,et al.  The emerging role of lysophosphatidic acid in cancer , 2003, Nature Reviews Cancer.

[34]  K. Tasaka,et al.  Lysophosphatidic acid induces focal adhesion assembly through Rho/Rho-associated kinase pathway in human ovarian cancer cells. , 2002, Gynecologic oncology.

[35]  G. Mills,et al.  In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  Yan Xu,et al.  Lysophospholipids increase interleukin-8 expression in ovarian cancer cells. , 2001, Gynecologic oncology.

[37]  Shuang Huang,et al.  Lysophosphatidic Acid Stimulates Ovarian Cancer Cell Migration via a Ras-MEK Kinase 1 Pathway , 2004, Cancer Research.

[38]  Y. Xu,et al.  Phorbol 12-myristate 13-acetate stimulates lysophosphatidic acid secretion from ovarian and cervical cancer cells but not from breast or leukemia cells. , 1998, Gynecologic oncology.

[39]  D. Fishman,et al.  LPA-induced epithelial ovarian cancer (EOC) in vitro invasion and migration are mediated by VEGF receptor-2 (VEGF-R2). , 2005, Gynecologic oncology.

[40]  S. Frisch,et al.  The G12/13-RhoA signaling pathway contributes to efficient lysophosphatidic acid-stimulated cell migration , 2006, Oncogene.

[41]  D. Fishman,et al.  Lysophosphatidic acid enhances epithelial ovarian carcinoma invasion through the increased expression of interleukin-8. , 2004, Gynecologic oncology.

[42]  M. Stack,et al.  Cyclooxygenase-2 functions as a downstream mediator of lysophosphatidic acid to promote aggressive behavior in ovarian carcinoma cells. , 2005, Cancer research.